Elsevier has announced enhancements to Reaxys Medicinal Chemistry that address the critical workflow and data challenges of early drug discovery
As not only the HPC industry but the larger computing ecosystem tries to overcome the slowdown and eventual end of transistor scaling described by Moore’s Law, scientists and researchers are implementing programmes that will define the technologies and new materials needed to supplement, or repla
Architectural specialisation is one option to continue to improve performance beyond the limits imposed by the slow down in Moore’s Law.
As the complexity of both HPC hardware and the challenges that scientists are trying to solve using HPC systems increases, ensuring a system is utilised efficiently is necessary to deliver a computing service with value for money and a high research output.
With data rates increasing and more complex challenges arising in life sciences, Panasas’ Jim Donovan and Dale Brantly discuss the benefits of using HPC for these workloads
